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Abstract 
Purpose: To investigate the modulatory effects of phytoestrogens (coumestrol, daidzein and genistein) 
and curcumin on the induction and secretion of annexin-1 (ANXA-1) in human peripheral blood 
mononuclear cells (PBMCs) under inflammatory and non-inflammatory conditions, as well as their effect 
on the activity of phospholipase A2-V (sPLA2-V). 
Methods: The modulatory effects of phytoestrogens and curcumin on the induction ofANXA1 were 
investigated via sandwich ELISA method, while their effects on the activity of sPLA2-V were determined 
by photometric assays. Besides, the cell viability of these compounds was determined by standard 
trypan blue exclusion method using PBMCs. 
Results: The results indicate a significant increase (p < 0.05) in the total content ofANXA1, particularly 
by coumestrol (p < 0.01), in both inflammatory and non-inflammatory cells. Besides, the compounds 
also exhibited a dose-dependent inhibition of sPLA2-V activity; however, among these compounds, 
curcumin and genistein were the strongest inhibitors with an IC50 value of 11.1 ± 0.3 µM and13.6 ± 0.6 
µM respectively. 
Conclusion: The investigated compounds have a potential to induce synthesis and secretion ofANXA1 
as well as inhibitory activity of sPLA2-V, suggesting their inhibitory role in phospholipid metabolism and 
inflammation. 
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Inflammation, a widely addressed issue with 
clinical implications, has attracted a lot of 
researchers in multiple disciplines. 
Mechanistically, inflammation is a complex set of 
interactions among soluble and cellular 
components, recruited at and by destruction of 
connective tissue. The major soluble 
components include certain intercellular 
messengers such as cytokines [1]. Among 
cellular components, blood-borne monocytes/ 
macrophages are an integral part of 
inflammation. 
 
Among all the anti inflammatory mediators, 
Annexin 1 (ANXA 1) has been proven to be the 
key anti-inflammatory mediator to control the 
inflammatory cascades.ANXA1 is a 37-kd protein 
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made up of 346 amino acids and the first 
member of the annexin super family of calcium 
and phospholipid binding proteins [2].ANXA1 and 
its N-terminal portion can influence many 
inflammatory mechanisms and regulate the 
synthesis of eicosanoids, leukocyte migration 
and apoptosis of inflammatory cells [3]. The 
ability ofANXA1 to regulate the synthesis of 
inflammatory mediators (such as eicosanoids) is 
due to its ability to restrain the activity of 
phospholipase A2 (PLA2). PLA2 is the only super 
family of esterases that slices the acyl ester 
linkage at the sn-2 site of membrane 
phospholipids, liberating free fatty acids and 
lysophospholipids [4]. These hydrolases are pro-
inflammatory cytokines responsible for the 
release of arachidonic acid and eicosanoids 
synthesis.  PLA2 can be segregated into three 
major classes, Ca+2 dependent cytosolic PLA2 
(cPLA2), Ca+2 independent cytosolic PLA2 (iPLA2) 
and secretory PLA2 (sPLA2). Amongst these, 
sPLA2s are the main contributors for the 
extensive production of arachidonic acid in 
inflammatory pathways [5]. 
 
To counteract the mediators of inflammatory 
cascades, a number of anti-inflammatory agents 
have been used. Among these, glucocorticoids 
(GCs) are the mainstay for the management of 
various inflammatory and immune disorders. 
GCs inhibit inflammation through a series of 
mechanisms, of which the induction ofANXA1 is 
a key mechanism. However, adverse effects 
associated with their long-term usage and 
development of resistance limit the use of GCs in 
chronic maintenance therapies. Among these 
deleterious effects, adrenal atrophy, cushing 
syndrome, hypertension, gastrointestinal 
bleeding, hypo-gonadism and fetal growth 
retardation [6] are associated with the long-term 
use of GCs. Considering the above mentioned 
clinical complications, global focus is to discover 
safer and more efficacious agents. 
 
Curcumin, a natural compound found in curcuma 
species has been used successfully as an anti-
inflammatory agent. The pharmacological 
perspective of curcumin is under investigation 
and includes demonstration of its targets such as 
transcription factors, cytokines, cell adhesion 
molecules, surface receptors, growth factors and 
various kinases [7] thereby, causing either direct 
cellular pathway inhibition or activation of 
secondary cellular responses. 
 
Furthermore, coumestrol, genistein and daidzein 
sourced from soybeans are the phytoestrogens.  
Phytoestrogens are substances that promote 
estrogenic actions in mammals and structurally 
resemble mammalian estrogen 17β-estradiol [8].  
They mimic the biological activity of estrogens 
and have wide range of biological activities 
including estrogenic, antioxidant, anti 
inflammatory, antithrombotic, anti allergic, 
hypolipidemic and anti cancer properties [9].  
Many biological and anti inflammatory effects of 
curcumin and phytoestrogens have been 
reported.  However, to the best of our 
knowledge, their ability to modulate the induction 
ofANXA1 has not been reported to date. 
Therefore, the aim of the current study was to 
investigate the effect of phytoestrogens and 
curcumin on the induction ofANXA1 in human 
peripheral blood mononuclear cells as well as 
their inhibitory effects on the secretory 






Curcumin, coumestrol, daidzein and genistein 
were obtained from Sigma, Steinheim Germany. 
Compounds were dissolved in 5 % dimethyl 
sulfoxide (DMSO) (Sigma, Steinheim, Germany) 
and diluted with PBS (phosphate-buffered saline) 
to obtain stock solutions of 1mg/mL. For the 
concentrations used in assay, calculated amount 
of stock solution were taken and diluted with 
complete medium. Complete medium consisted 
of RPMI-1640 supplemented with L-glutamin 
(Sigma, Steinheim, Germany), 10 % heat-
inactivated newborn calf serum (Sigma, 
Steinheim, Germany), 10 mM HEPES (Sigma, 
Steinheim, Germany), and 100 U/ml penicillin 
and 100 µg/ml streptomycin (PAA, Pasching, 
Austria). The final concentration of DMSO in the 
solution applied to the PBMC was < 0.01%. 
 
Separation of human peripheral blood 
mononuclear cells (PBMCs)  
 
PBMCs were obtained from blood donated by 
healthy volunteers. This study was approved by 
the human ethical committee of Universiti 
Kebangsaan Malaysia (UKM) (approval no. UKM 
1.5.3.5/244/NF-050-2012) and conformed to the 
principles outlined in the Declaration of Helsinki 
[23]. Venous blood was collected in heparinized 
tubes and processed right away. Human PBMCs 
were isolated using gradient centrifugation in 
Lympoprep (Axis-Shield PoC AS, Oslo, Norway). 
Blood was diluted at 1:2 with RPMI-1640 
medium, carefully layered on Lymphoprep, and 
centrifuged at 600 g for 20 min at 20 oC. The 
PBMCs layer was removed and washed twice 
with RPMI-1640 and re-suspended in RPMI-1640 
complete medium in a culture tube. The cells 
were adjusted to 5x105 cells/ml by using 
haemocytometer. 
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Cell viability  
 
Cell viability was determined by the standard 
trypan blue exclusion method. The PBMCs (5 x 
105 cells/ml) were incubated with various 
concentrations of the compounds ranging from 5 
to 100 µg/ml, each in triplicate at room 
temperature for overnight. The blue dye uptake 
was a signal of cell death. The percentage 
viability was calculated from the total cell counts. 
The concentration of compounds at which 
viability was > 95% was used for further studies 
[10]. 
 
Incubation of compounds in inflammatory 
and non-inflammatory PBMCs   
 
PBMCs were incubated overnight at 37 °C and 5 
% CO2 either in the presence or in the absence 
of the test compounds.  PBMCs were stimulated 
by 1 µg/mL of lipopolysaccharide (LPS) from 
Salmonella enteritica (Sigma, Steinheim, 
Germany) for the inflammatory condition.  
Dexamethasone at 0.4 µg/mL (10-6 M) was used 
as a positive control and a mixture containing 
DMSO, PBS and RPMI-1640 was used as a 
negative control. Control groups were taken for 
stimulated as well as for non-stimulated PBMCs 
[11]. 
 
Extraction of extracellular, intracellular and 
cell surface-associated Annexin 1  
 
Following incubation period, cells were gently 
centrifuged (300 g) for 5 min at 4 °C and the 
supernatant was separated for extracellular 
ANXA1. This centrifugation did not cause any 
lysis. The membrane bound ANXA1 was 
removed into the medium by washing the cells 
with Ca+2 free salt solution containing EDTA 
(Sigma, Steinheim, Germany). The pelleted cells 
were re-suspended in PBS containing 2 mM 
EDTA and were further incubated for 2-3 min to 
get rid of ANXA1 attached to cell membranes. 
After incubation, cells were centrifuged again at 
the specifications mentioned before. The 
supernatant was isolated for measurement of 
membrane bound ANXA1. Subsequent to the 
removal of membrane associated ANXA1, cells 
were lysed and the lysate was taken for the 
calculation of entire intracellular ANXA1 [10]. 
 
Quantification of Annexin 1 by ELISA 
 
ANXA1 was deliberated by sandwich Enzyme 
linked-immunosorbent Assay (ELISA) (USCN 
Life Science, China). The whole assay was 
performed as described by the manufacturer. 
ELISA was performed in duplicate, and data was 
obtained from three different donors. 
Inhibition of secretory Phospholipase A2 –V 
(sPLA2-V) Assay   
 
Human recombinant sPLA2-V (Cayman) was 
employed as enzyme source. The activity of 
sPLA2 enzyme was calculated by a photometric 
assay based on the Ellman method [12]. Briefly, 
hydrolysis of sn-2 ester bond of the substrate 
1,2-bis(heptanoylthio)-glycerophosphocholine by 
PLA2-V was followed by the exposure of free 
thiols. These thiols triggered the alteration of 
DTNB (5,5–dithio-bis-(2-nitrobenzoic acid) to 2-
nitro-5-thiobenzoic acid which was detected 
photometrically at 405 nm. Afterwards, the assay 
was progressed in an aqueous buffer solution 
(pH 7.5) containing KCl (94 mM), CaCl2 (9 mM), 
Tris (24 mM) and Triton-X 100 (280 µM ).  Prior 
to the assay, substrate and PLA2-V were re-
suspended in assay buffer, and DTNB was 
dissolved in an aqueous solution of Tris-HCl (pH 
8). Enzyme and DTNB yielded final 
concentrations of 100 ng/mL and 87 µM 
respectively. Assays were performed in 96-well 
microliter plates at room temperature containing 
DTNB, substrate solution and the respective test 
substance. 100% activity of enzyme was 
calculated by adding substrate and enzyme only. 
DMSO served as a negative control and was 
inactive at the concentration used in the assay 
(1.7 %v/v). 
 
Statistical analysis  
 
The results are expressed as mean ± standard 
deviation. All statistical analyses were performed 
using Graph Pad Prism 5. One-way ANOVA, 
followed by a post-test (Tukey’s multiple 
comparison) was carried out when major 




Cell viability  
 
The cell viability was assessed prior to every 
experiment. The viability of PBMCs incubated in 
the presence of test compounds at 
concentrations 10 µg/mL was always greater 
than 95%. The concentrations of compounds 
higher than 10µg/mL decreased the cell viability 
below 95%.  
 
Effect on annexin-1 level and secretion in 
normal PBMC  
 
The modulation of ANXA1 from PBMCs was 
observed by incubating the PBMC either in the 
presence or in the absence of curcumin, 
coumestrol, ginestein and diadzine at 10 µg/mL 
for all compounds. After incubation, intracellular, 
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Figure 1: (a) Concentration of extracellular, intracellular and plasma membrane bound levels of ANXA1 in PBMC 
in the absence of compounds (control), Dexamethasone (0.4 µg/mL) and in the presences of compounds (10 
µg/mL). (b) Total content of ANXA1 level in PBMC. 
 
extracellular and membrane bound ANXA1 levels 
were calculated as described in methods. 
Considerable increase was observed in the basal 
levels of intracellular ANXA1 with all compounds; 
however, coumestrol exhibited maximum 
increase in the intracellular level of ANXA1. A 
significant increase in the level of extracellular 
ANXA1 was found for all the compounds as 
compared to control (Figure 1a). Results 
presented in Figure 1a illustrate an increase in 
plasma membrane bound ANXA1 and 
statistically significant increase by coumestrol. 
These results designate the induction of 
synthesis and stimulation of secretion of ANXA1 
in PBMCs. 
Collectively, a manifold increase in total level of 
ANXA1 was observed after combining the 
extracellular, intracellular and membrane bound 
contents of ANXA1 (Figure 1b). As compared to 
the untreated cells (8.1 ± 0.4 ng/mL), the total 
content of ANXA1 was substantially increased 
(21.5 ± 0.8 ng/mL) with coumestrol. With 
curcumin, genistein and daidzein, the level of 
ANXA1 increased to 14.7 ± 1.1, 13.2 ± 0.4 and 
12.8 ± 0.3 ng/mL respectively. Amongst all, 
coumestrol exhibited the strongest stimulation of 
ANXA1. On the other hand, curcumin also 
showed worth mentioning results. Ginestein and 
diadzine also moderately up regulated ANXA1. 
 
Effect on Annexin-1 level and secretion in 
inflammatory PBMCs  
 
The levels of ANXA1 were also measured in 
inflammatory conditions. For this purpose, 
PBMCs taken from the same blood donors were 
subjected to inflammatory condition. Intracellular, 
extracellular and membrane bound ANXA1 level 
was measured as described above. Figure 2a 
illustrates an increase in the extracellular level of 
ANXA1 in stimulated PBMCs, relative to control. 
An increase in intracellular and plasma 
membrane-bound ANXA1 was also observed. 
In inflammatory PBMC, a net increase was seen 
in the total content (extracellular, intracellular and 
membrane bound) of ANXA1. The level of 
ANXA1 increased to 15 ± 0.7 and 11.5 ± 0.9 
ng/mL for coumestrol and curcumin, respectively.  
Likewise, an increasing trend was seen for 
ginestein (8.9 ± 0.3 ng/mL) and diadzine (9.8 ± 
0.3 ng/mL), correspondingly. For all the 
compounds, an increasing trend in the levels of 
ANXA1 was seen in both normal and 
inflammatory cells. Similar to non- inflammatory 
condition, the potency of coumestrol was also 
highest in inflammatory condition.  
 
Inhibition of sPLA2-V   
 
Secretory PLA2 inhibitory activity was determined 
using the Ellman method. The activity was 
assessed by detecting free thiols using Ellman’s 
reagent DTNB (5, 5’-Dithio-2 nitrobenzoic acid). 
The inhibition of sPLA2 activity from human 
source was determined by different 
concentrations of the inhibitors. The IC50 values 
for sPLA2 were calculated by linear XY scattered 
plot (Table 1). The inhibition of sPLA2 activity 
varied for different inhibitors at different 
concentrations. ANXA1 inhibited sPLA2 in a 
dose-dependent manner.  As the concentration 
of ANXA1 was increased, a corresponding 
decrease in the enzyme activity was 
observed.ANXA1 preferentially inhibited sPLA2 
enzyme activity with an IC50 value of 4.9 x 10-7 
and showed > 80% at 400 ng/mL.  
Dexamethasone also exhibited sPLA2 inhibition 
in a dose dependent manner with an IC50 value 
of 0.61 ± 0.1 µM (Figure 3 and Table 1). 
Similarly, curcumin, genistein and daidzein 
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inhibited the sPLA2 activity in a concentration 
dependent manner (Figure 4 and Table 1). Of all 
the compounds, curcumin exhibited the strongest 
inhibition on sPLA2 enzyme activity with an IC50 
value of 11.1 ± 0.3 µM.  Among the 
phytoestrogens, genistein showed the strongest 
activity with an IC50 value of 13.6 ± 0.6 µM. 
Coumestrol also moderately inhibited sPLA2 
activity in a concentration dependent manner  
 
Figure 2: 
(a) Concentration of extracellular, intracellular and plasma membrane bound levels of ANXA1 in inflammatory 
PBMC in the absence of compounds (control), Dexamethasone (0.4 µg/mL) and in the presence of compounds 
(10 µg/mL). (b) Total content of ANXA1 level in inflammatory PBMCs. 
 
 
Figure 3: Concentration-dependent inhibition of 
sPLA2 enzyme by annexin-1(circle) and 
dexamethasone (square). Inhibition is expressed as 
percent of control. The data represents mean ± SD (n 
= 3).  
 
Table 1:  IC50 (µM) values of phytoestrogens, 
curcumin and annexin 1 against   sPLA2 –V activity 
 










ANXA1 role as an anti-inflammatory protein has 
been brought to limelight in recent years. ANXA1 
was initially thought to be just a cytosolic protein  
  
Figure 4: Concentration-dependent inhibition of 
sPLA2-V enzyme by curcumin, coumestrol, genistein 
and daidzein. Inhibition is expressed as percent of 
control. The data represents mean ± SD (n = 3).  
 
to exert its anti-inflammatory effects through 
inhibition of PLA2. However, recent studies on 
ANXA1 have uncovered new effects and actions 
of ANXA1. In resting conditions, human 
neutrophils, monocytes and macrophages 
constitutively contain ANXA1 [13]. ANXA1 
expression and function with GCs treatment are 
already known but the intracellular signalling 
pathways involved in the expression of ANXA1 in 
response to steroidal hormones are still unclear. 
Although some reports have illustrated that GCs 
up-regulate ANXA1 synthesis by genomic 
mechanisms [14], different intracellular studies 
state that this effect is independent of the 
activation of nuclear GCs receptors. In 
agreement with these reports, a recent study 
reported that in CCRFCEM cells, ANXA1 
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synthesis was independent of the nuclear GCs 
receptors [15]. Dexamethasone significantly 
increases the cellular content of ANXA1 when 
incubated overnight. The overnight incubation of 
PBMCs with 10 µg/mL of investigated 
compounds result in the up-regulation of ANXA1. 
Moreover, a significant increase in the amount of 
ANXA1 excreted out of plasma membrane was 
also observed. It has been reported that the 
increase in the cellular turnover ofANXA1 may 
cause a rapid export of the proteins from 
intracellular stores to extracellular sites and as a 
consequence the de novo synthesis of proteins 
may took place to replenish the depleted 
intracellular levels [16]. Based on these findings, 
our results indicate that the investigated 
compounds may have a potential to efficiently 
stimulate the ANXA1 secretion.  
 
Recent studies on the induction of ANXA1 
expression have shown that chemically similar 
estrogen hormones also have role in the 
induction of the ANXA1. In studies carried out 
previously, researchers had demonstrated that in 
human lymphoblastic CCRF-CEM cell line, 
estrogen hormone and 17 β-estradiol (E2β) 
induced the synthesis of ANXA1 [15].   It is well 
established that E2β exerts major effects on cell 
growth, differentiation and function by specifically 
interacting with intracellular estrogen receptors 
(ER) [17]. The complex E2β -ER migrates to the 
nucleus of the cells, where it binds to estrogen-
responsive elements present in the genomic 
DNA.  It was reported that the up-regulation of 
ANXA1 was due to the action of E2β on estrogen 
receptors. 
 
Coumestrol, genistein and diadzine are 
phytoestrogens. Phytoestrogens promote 
estrogenic actions in mammals. Mechanistically, 
phytoestrogens have been shown to bind to two 
types of estrogen receptors: estrogen receptor α 
and receptor β, respectively. On the basis of 
above mentioned facts, it is hence proved that 
the investigated compounds resemble E2β in 
structure and functions, and also exhibit results 
similar to E2β. Curcumin is renowned for its anti 
inflammatory effects and treatment of various 
diseases. In this study, it has been observed that 
curcumin up-regulate ANXA1 in PBMC, but the 
mechanisms by which curcumin up regulate 
ANXA1 are still unknown.  
 
Among the PLA2 enzymes, sPLA2 enzymes play 
an important role in the pathogenesis of 
inflammatory diseases [18]. Elevated levels of 
sPLA2 enzymes are detected in many 
inflammatory conditions. Inhibiting sPLA2s would 
probably be a preferable strategy since their 
induced levels are predominantly associated with 
pathological conditions. Though, a selective 
inhibition of just one isoform of sPLA2 may not be 
sufficient to exert the desired effect. The 
originally recognized activity of ANXA1 as an 
inhibitor of phospholipase A2 (PLA2) was at first 
proposed to be accountable for its anti 
inflammatory actions [19]. The inhibition of PLA2 
activity, including the production of arachadonic 
acid, was thought to be a result of ANXA1 
binding to the substrate, rather than directly to 
the enzyme, leading to the depletion of substrate 
sites and a subsequent reduction of PLA2 
activity. However, this idea was reassessed and 
it is now obvious that a secretory form (sPLA2) as 
well as a cytosolic form of PLA2 (cPLA2) exist. 
ANXA1 has shown the inhibition of sPLA2 in 
concentration dependent manner. The same 
mechanism has also been observed for cPLA2 
inhibition [20]. 
 
Anti inflammatory properties of GCs have been 
attributed to the liberation and enhanced 
synthesis of ANXA1, which inhibit PLA2, resulting 
in a decreased eicosanoid synthesis. However in 
the current study, dexamethasone has been 
found to have inhibited the sPLA2 in a 
concentration dependent manner. In the previous 
studies, dexamethasone had been reported to 
inhibit the PLA2 in U937 cells but, the expression 
of ANXA1 was not inducible by GCs in these 
cells [21].  
 
Flavonoids are antioxidants known to act as anti-
inflammatory compounds by scavenging the free 
radicals. Therefore, a single molecule having 
both potencies of PLA2 inhibition as well as 
antioxidant activity can serve as a better anti-
inflammatory molecule. In the present study, the 
flavonoids, genistein and diadzine inhibited 
sPLA2-V in a concentration dependent manner. 
Many inhibitors inhibit the sPLA2 activity either by 
binding to the substrate, or by chelating with 
calcium. But the inhibition of other sPLA2 isomers 
by genistein was observed to be independent of 
substrate and chelation of calcium, though sPLA2 
isomers exhibited more than 70% homology [22]. 
Diadzine and genistein belong to same class and 
have structural and functional similarities. So, it is 
possible that diadzine has same mechanism as 




The results illustrate that the phytoestrogen and 
curcumin have potentials to induce synthesis and 
secretion of ANXA1 in peripheral blood 
mononuclear cells (PBMCs). Our findings on 
sPLA2-V inhibition provide further evidence to 
rationalize the anti-inflammatory activities of the 
tested compounds. The present findings on 
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sPLA2-V inhibitory functionality should encourage 
further investigations that would address other 
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